The biotechnology company discloses disappointing trial data for two treatments for Duchenne muscular dystrophy.

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel ...

Embargoed for 9am CET (3am ET) on Monday November 3rdAmgen Ventures-backed AAVantgarde Bio has raised $143 million in series ...

Biotech raises $540M from DRW, ARK Invest for Canton Coin treasury. Shares surge 120% on Super Validator plans.

A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...

Editor’s Note: This deep dive was originally published Sept. 24, 2025, as a special edition of Biopharm Executive. Subscribe ...

Intellia Therapeutics also has fans on Wall Street. The company's current average price target of $32.3 (according to Yahoo!

Dimitri Semenikhin, the retail trader behind the Beyond Meat stock rally is piling into a small biotech that recently pivoted ...

Genmab A/S (NASDAQ: GMAB) is one of the most profitable biotech stocks to buy. H.C. Wainwright analyst Ram Selvaraju ...

Importantly, BGE-102 is an oral candidate. The current leaders in the anti-obesity market are administered via subcutaneous ...

ALBANY, Ore., Nov. 4, 2025 /PRNewswire/ -- Synergy Dental Partners and Oral BioTech are proud to announce a strategic partnership aimed at enhancing oral health care for dental professionals and their ...